SLC44A4 and neoplasm: For instance, anti-PD-1 ICB was thought to act primarily at the interface of T cells and tumor cells within the local tumor microenvironment, while anti-CTL4 ICB was shown to be able to act more upstream at the phase of T cells priming at the lymph nodes [13,148].